KR101949451B1 - 염증성 장 질환 및 아토피 피부염 치료용 조성물 - Google Patents

염증성 장 질환 및 아토피 피부염 치료용 조성물 Download PDF

Info

Publication number
KR101949451B1
KR101949451B1 KR1020160131313A KR20160131313A KR101949451B1 KR 101949451 B1 KR101949451 B1 KR 101949451B1 KR 1020160131313 A KR1020160131313 A KR 1020160131313A KR 20160131313 A KR20160131313 A KR 20160131313A KR 101949451 B1 KR101949451 B1 KR 101949451B1
Authority
KR
South Korea
Prior art keywords
atopic dermatitis
ips
ncs
dncb
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020160131313A
Other languages
English (en)
Korean (ko)
Other versions
KR20170043457A (ko
Inventor
강인철
Original Assignee
주식회사 이노파마스크린
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 이노파마스크린 filed Critical 주식회사 이노파마스크린
Priority to EP16855712.2A priority Critical patent/EP3363783B1/en
Priority to PCT/KR2016/011434 priority patent/WO2017065495A2/ko
Priority to HK18113385.6A priority patent/HK1254242B/zh
Priority to CN201680059836.6A priority patent/CN108137490B/zh
Priority to JP2018519833A priority patent/JP6885607B2/ja
Priority to US15/768,374 priority patent/US10278931B2/en
Publication of KR20170043457A publication Critical patent/KR20170043457A/ko
Application granted granted Critical
Publication of KR101949451B1 publication Critical patent/KR101949451B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020160131313A 2015-10-13 2016-10-11 염증성 장 질환 및 아토피 피부염 치료용 조성물 Expired - Fee Related KR101949451B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP16855712.2A EP3363783B1 (en) 2015-10-13 2016-10-12 Composition for treatment of inflammatory bowel disease and atopic dermatitis
PCT/KR2016/011434 WO2017065495A2 (ko) 2015-10-13 2016-10-12 염증성 장 질환 및 아토피 피부염 치료용 조성물
HK18113385.6A HK1254242B (zh) 2015-10-13 2016-10-12 用於治疗炎性肠病和异位性皮炎的组合物
CN201680059836.6A CN108137490B (zh) 2015-10-13 2016-10-12 用于治疗炎性肠病和异位性皮炎的组合物
JP2018519833A JP6885607B2 (ja) 2015-10-13 2016-10-12 炎症性腸疾患およびアトピー性皮膚炎の処置のための組成物
US15/768,374 US10278931B2 (en) 2015-10-13 2016-10-12 Composition for treatment of inflammatory bowel disease and atopic dermatitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150142929 2015-10-13
KR20150142929 2015-10-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020170155266A Division KR101901895B1 (ko) 2015-10-13 2017-11-21 염증성 장 질환 및 아토피 피부염 치료용 조성물

Publications (2)

Publication Number Publication Date
KR20170043457A KR20170043457A (ko) 2017-04-21
KR101949451B1 true KR101949451B1 (ko) 2019-05-10

Family

ID=58705365

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020160131313A Expired - Fee Related KR101949451B1 (ko) 2015-10-13 2016-10-11 염증성 장 질환 및 아토피 피부염 치료용 조성물
KR1020170155266A Active KR101901895B1 (ko) 2015-10-13 2017-11-21 염증성 장 질환 및 아토피 피부염 치료용 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020170155266A Active KR101901895B1 (ko) 2015-10-13 2017-11-21 염증성 장 질환 및 아토피 피부염 치료용 조성물

Country Status (5)

Country Link
US (1) US10278931B2 (enExample)
EP (1) EP3363783B1 (enExample)
JP (1) JP6885607B2 (enExample)
KR (2) KR101949451B1 (enExample)
CN (1) CN108137490B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101949451B1 (ko) * 2015-10-13 2019-05-10 주식회사 이노파마스크린 염증성 장 질환 및 아토피 피부염 치료용 조성물
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
CN114681438B (zh) * 2022-05-17 2024-03-19 中国医学科学院基础医学研究所 二甲双胍及其它含胍化合物在逆转Gal-10结晶趋势并缓解相关疾病中应用
CN119970807A (zh) * 2025-03-07 2025-05-13 中国人民解放军总医院第一医学中心 Tslp表达水平调节剂及治疗银屑病的药物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
US20130095140A1 (en) * 2011-01-07 2013-04-18 Elcelyx Therapeutics, Inc. Biguanide Compositions and Methods of Treating Metabolic Disorders
KR101901895B1 (ko) * 2015-10-13 2018-09-27 주식회사 이노파마스크린 염증성 장 질환 및 아토피 피부염 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004005509A1 (ja) * 2002-07-02 2005-11-04 株式会社ジェノックス創薬研究所 アレルギー性疾患の検査方法、および治療のための薬剤
WO2009113092A2 (en) 2008-01-23 2009-09-17 Usv Limited Process for preparation of proguanil hydrochloride
KR20110010763A (ko) * 2008-05-09 2011-02-07 톨마 인코포레이티드 피부/점막 질환을 치료하기 위한 프로구아닐
KR101274981B1 (ko) 2010-01-06 2013-06-18 한올바이오파마주식회사 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
KR102231554B1 (ko) * 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법
WO2015026215A1 (ko) 2013-08-23 2015-02-26 가톨릭대학교 산학협력단 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물
WO2015167243A1 (ko) * 2014-04-29 2015-11-05 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR101705446B1 (ko) 2014-04-29 2017-02-09 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR102216701B1 (ko) 2014-11-20 2021-02-18 이뮤노메트테라퓨틱스 인코포레이티드 바이구아나이드 화합물 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
US20130095140A1 (en) * 2011-01-07 2013-04-18 Elcelyx Therapeutics, Inc. Biguanide Compositions and Methods of Treating Metabolic Disorders
KR101901895B1 (ko) * 2015-10-13 2018-09-27 주식회사 이노파마스크린 염증성 장 질환 및 아토피 피부염 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstract 화합물, STN express. RN 300382-90-5 (Entered STN: 2000.10.30. 공개)*

Also Published As

Publication number Publication date
EP3363783A2 (en) 2018-08-22
KR20170043457A (ko) 2017-04-21
US10278931B2 (en) 2019-05-07
US20180303774A1 (en) 2018-10-25
CN108137490B (zh) 2021-09-03
JP2018536638A (ja) 2018-12-13
KR20170131325A (ko) 2017-11-29
EP3363783B1 (en) 2021-12-08
JP6885607B2 (ja) 2021-06-16
CN108137490A (zh) 2018-06-08
EP3363783A4 (en) 2019-05-29
KR101901895B1 (ko) 2018-09-27
HK1254242A1 (zh) 2019-07-12

Similar Documents

Publication Publication Date Title
KR101901895B1 (ko) 염증성 장 질환 및 아토피 피부염 치료용 조성물
Zhang et al. Luteolin activates Tregs to promote IL-10 expression and alleviating caspase-11-dependent pyroptosis in sepsis-induced lung injury
Tang et al. Topical application of glycolic acid suppresses the UVB induced IL-6, IL-8, MCP-1 and COX-2 inflammation by modulating NF-κB signaling pathway in keratinocytes and mice skin
Bibi et al. Dietary red raspberries attenuate dextran sulfate sodium-induced acute colitis
Herrera-Aco et al. Alpha-mangostin: Anti-inflammatory and antioxidant effects on established collagen-induced arthritis in DBA/1J mice
Lee et al. The prevention of TNF-α/IFN-γ mixture-induced inflammation in human keratinocyte and atopic dermatitis-like skin lesions in Nc/Nga mice by mineral-balanced deep sea water
Abdou et al. The potential therapeutic effects of Trifolium alexandrinum extract, hesperetin and quercetin against diabetic nephropathy via attenuation of oxidative stress, inflammation, GSK-3β and apoptosis in male rats
Arab et al. Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling
Park et al. AMPK activation reduces vascular permeability and airway inflammation by regulating HIF/VEGFA pathway in a murine model of toluene diisocyanate-induced asthma
Lin et al. Anti-atherosclerotic effects of geraniin through the gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway in mice
Ko et al. Genipin inhibits allergic responses in ovalbumin-induced asthmatic mice
Yang et al. Jageum-Jung improves 2, 4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice and suppresses pro-inflammatory chemokine production by inhibiting TNF-α/IFN-γ-induced STAT-1 and NFκB signaling in HaCaT cells
Zhang et al. Biochanin a ameliorates DSS-induced ulcerative colitis by improving colonic barrier function and protects against the development of spontaneous colitis in the Muc2 deficient mice
Pramanik et al. Serine protease inhibitors rich Coccinia grandis (L.) Voigt leaf extract induces protective immune responses in murine visceral leishmaniasis
Kim et al. Papain suppresses atopic skin inflammation through Anti-Inflammatory activities using in vitro and in vivo models
Gao et al. Inhibitory effect of Incarvillea diffusa Royle extract in the formation of calcium oxalate nephrolithiasis by regulating ROS-induced Nrf2/HO-1 pathway in rats
Keivanpour et al. 6-Gingerol anti-inflammatory and antioxidant properties protect against heart and liver dysfunction in rats with sepsis
Abdelmawgood et al. 4-Hydroxychalcone attenuates ovalbumin-induced allergic airway inflammation and oxidative stress by activating Nrf2/GPx4 pathway
Mohamad et al. Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway
Guo et al. Baicalin n-butyl ester alleviates inflammatory bowel disease and inhibits pyroptosis through the ROS/ERK/P-ERK/NLRP3 pathway in vivo and in vitro
Hu et al. Astragaloside IV attenuates podocyte apoptosis via regulating TXNIP/NLRP3/GSDMD signaling pathway in diabetic nephropathy
Ramos-Tovar et al. Cirrhosis induced by thioacetamide is prevented by stevia. Molecular mechanisms
Miyake et al. Oral administration of highly oligomeric procyanidins of Jatoba reduces the severity of collagen-induced arthritis
US20240082131A1 (en) Composition for improving skin conditions
Zhang et al. Evaluation of the therapeutic effect of Sacha inchi oil in atopic dermatitis mice

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250213

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250213